Victory Capital Management
SCLN

Victory Capital Management’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Victory Capital Management’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-6,298
Closed -$68K – 1904
2016
Q4 		$68K Sell
6,298
-154
-2% -$1.54K ﹤0.01% 1668
2016
Q3 		$66K Buy
+6,452
New +$70.3K ﹤0.01% 1668

Other funds holding SCLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Victory Capital Management's SCLN Position: Q1 2017 in Review

Victory Capital Management sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q1 2017, closing a stake of 6,298 shares — an estimated $68K sold.

Victory Capital Management first reported a position in SCLN in Q3 2016 and held it in 2 quarters. The position peaked at $68K in Q4 2016. 136 funds tracked by Wall St. Rank hold SCLN as of Q1 2017.

  • Victory Capital Management reported no remaining Sciclone Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
  • Victory Capital Management sold 6,298 Sciclone Pharmaceuticals Inc shares in Q1 2017, an estimated $68K.
  • Victory Capital Management first reported a position in Sciclone Pharmaceuticals Inc in Q3 2016 and held it in 2 quarters.
  • Victory Capital Management's Sciclone Pharmaceuticals Inc position peaked at $68K in Q4 2016.
  • 136 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q1 2017.

Based on Victory Capital Management's 13F filing for Q1 2017, filed 10 May 2017.